v3.26.3
Schedule of segment reporting information, by segment (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Jun. 30, 2026
USD ($)
Mar. 31, 2026
USD ($)
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2026
USD ($)
SEGMENT
Sep. 30, 2025
USD ($)
Segment Reporting Information [Line Items]                
Number of operating segments | SEGMENT             2  
Number of reporting segments | SEGMENT             2  
Operating expenses:                
Personnel and related expenses $ 3,372     $ 2,817     $ 9,320 $ 8,395
Office space rental related expenses 1,030     1,057     3,137 3,403
Development expenses 1,191     1,083     3,182 3,154
Professional services and insurance 1,269     1,373     3,828 4,656
Depreciation 129     105     387 307
Other general and administrative expenses 541     290     1,499 831
Other income (expense), net (282)     (195)     (953) (770)
Segment net loss 7,250 $ 6,370 $ 6,780 6,530 $ 7,144 $ 6,302 20,400 19,976
Biopharm Division [Member]                
Operating expenses:                
Personnel and related expenses 2,927     2,521     8,175 7,580
Office space rental related expenses 1,001     1,003     3,044 3,143
Development expenses 1,191     1,083     3,182 3,154
Professional services and insurance 984     1,201     3,202 4,018
Depreciation 129     101     387 299
Other general and administrative expenses 439     180     1,225 563
Other income (expense), net (280)     (237)     (614) (894)
Segment net loss 6,391     5,852     18,601 17,863
Neurostimulation Division [Member]                
Operating expenses:                
Personnel and related expenses 445     296     1,145 815
Office space rental related expenses 29     54     93 260
Development expenses        
Professional services and insurance 285     172     626 638
Depreciation     4     8
Other general and administrative expenses 102     110     274 268
Other income (expense), net (2)     42     (339) 124
Segment net loss $ 859     $ 678     $ 1,799 $ 2,113